Dai ichi Life Insurance Company Ltd Reduces Stock Holdings in Cencora, Inc. $COR

Dai ichi Life Insurance Company Ltd lowered its stake in Cencora, Inc. (NYSE:COR) by 5.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 84,741 shares of the company’s stock after selling 5,238 shares during the period. Cencora accounts for approximately 0.8% of Dai ichi Life Insurance Company Ltd’s holdings, making the stock its 25th biggest holding. Dai ichi Life Insurance Company Ltd’s holdings in Cencora were worth $26,621,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Assetmark Inc. raised its stake in Cencora by 57.0% in the fourth quarter. Assetmark Inc. now owns 67,281 shares of the company’s stock worth $22,724,000 after buying an additional 24,431 shares in the last quarter. ExodusPoint Capital Management LP purchased a new stake in Cencora in the fourth quarter worth about $16,487,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Cencora by 162.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 289,370 shares of the company’s stock valued at $97,735,000 after acquiring an additional 179,086 shares in the last quarter. Impact Partnership Wealth LLC bought a new stake in Cencora during the 1st quarter valued at approximately $1,170,000. Finally, SEB Asset Management AB bought a new stake in Cencora during the 1st quarter valued at approximately $134,139,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Up 1.5%

Shares of Cencora stock opened at $309.67 on Friday. The company has a 50-day simple moving average of $284.52 and a two-hundred day simple moving average of $316.47. The stock has a market capitalization of $60.25 billion, a PE ratio of 23.75, a price-to-earnings-growth ratio of 1.69 and a beta of 0.58. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The firm had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora announced that its board has approved a stock repurchase plan on Thursday, May 21st that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 3.9% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is currently 18.40%.

Insider Buying and Selling

In other Cencora news, Director Lauren M. Tyler bought 550 shares of Cencora stock in a transaction on Monday, June 22nd. The stock was acquired at an average price of $270.23 per share, with a total value of $148,626.50. Following the acquisition, the director owned 4,359 shares in the company, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.38% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Weiss Ratings lowered Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 30th. William Blair assumed coverage on Cencora in a research report on Tuesday, April 28th. They set a “market perform” rating on the stock. Citigroup reduced their price target on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Morgan Stanley set a $342.00 price objective on Cencora in a report on Friday, May 8th. Finally, Bank of America raised their price objective on Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a research report on Wednesday, June 24th. Eleven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $367.75.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.